Stock Comparison

ABBV vs BSX

AbbVie Inc vs Boston Scientific Corp

The Verdict

Dead heat. Both scored 0.1/10.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

BSX

Boston Scientific Corp

0.1

out of 10

Distressed

Head-to-Head

$381.1B

Market Cap

$79.7B

104.8

P/E Ratio

22.4

5.8%

Profit Margin

17.3%

95.6%

Return on Equity

12.6%

20.2

Debt-to-Equity

0.5

Moderate

Overall Risk

Moderate

0.1

DVR Score

0.1

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

BSX0.1/10

Boston Scientific (BSX) is a well-established large-cap medical device company. While it demonstrates solid financial health and consistent, healthy operational growth (Q1 2026 revenue +11.6% reported, +9.4% organic) and strategic acquisitions (like the proposed Penumbra deal), its fundamental profile is misaligned with 10x growth potential within 3-5 years. A market capitalization of $80.16 billi...

Full BSX Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.